2001
DOI: 10.1007/s11886-001-0081-2
|View full text |Cite
|
Sign up to set email alerts
|

Cardiac markers in the diagnosis of acute coronary syndromes

Abstract: Evolution of the role of cardiac markers has ranged from the diagnosis of acute myocardial infarction in patients with nondiagnostic electrocardiograms to prognostic risk stratification and to guide therapy. The technology to provide rapid, real time measurements by immunoassay has provided the laboratory and clinician with a range of test options. The principal changes have been the use of rapid serial marker measurements of well-recognized cardiac markers, and the development of immunoassays for the cardiac … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2008
2008
2020
2020

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 47 publications
0
2
0
Order By: Relevance
“…The reportable range is 0.0-50.0 ng/mL for cTnI and 0.0-150.0 ng/mL for CK-MB. Diagnosis of the potential risk of exercise-induced myocardial injury was done by comparing the post-exercise maximal value of cTnI with the myocardial injury cut-off of 0.06 ng/mL, according to the guidelines of European Society of Cardiology and American College of Cardiology (Alpert et al, 2000) and the acute myocardial infarction (AMI) cut-off of 0.50 ng/mL (Collinson and Chamberlain, 2001).…”
Section: Biomarkers Of Cardiac Damagementioning
confidence: 99%
“…The reportable range is 0.0-50.0 ng/mL for cTnI and 0.0-150.0 ng/mL for CK-MB. Diagnosis of the potential risk of exercise-induced myocardial injury was done by comparing the post-exercise maximal value of cTnI with the myocardial injury cut-off of 0.06 ng/mL, according to the guidelines of European Society of Cardiology and American College of Cardiology (Alpert et al, 2000) and the acute myocardial infarction (AMI) cut-off of 0.50 ng/mL (Collinson and Chamberlain, 2001).…”
Section: Biomarkers Of Cardiac Damagementioning
confidence: 99%
“…[1] The measurement of cardiac troponin I levels (cTnI) is now a standard tool in the diagnosis of myocardial infarction and in stratifying the risk of an acute coronary syndrome in patients without renal failure. [2,3] In HD patients, previous generation cTnI immunoassays were not always sufficiently accurate, but accuracy depends largely on the assay used. In recent years, with the last generation immunoassays that use antibodies against the more stable region of the cardiac troponin I molecule, both diagnostic accuracy and analytical precision at low concentrations have improved considerably.…”
Section: Introductionmentioning
confidence: 99%